R-Tech Uno to use Novozymes ingredient in new eye therapy

Published: 16-Nov-2011
Ingredients

Albucult will be the key component in the treatment for dry eye syndrome

R-Tech Ueno has chosen Novozymes Biopharma’s Albucult recombinant human albumin for use in a treatment for dry eye syndrome.

The Japan-based global specialist in ophthalmology and dermatology treatments will use Albucult as a key component in its new therapy, which will be the first of its kind for the treatment of severe and moderate dry eye conditions.

Albucult is manufactured by Novozymes’ long-term technology partner, Kaketsuken, based in Kumamoto, Japan and marketed by Novozymes worldwide.

The prevalence of dry eye syndrome continues to increase, with the condition having the highest rate of diagnosis of all ophthalmic disorders. Novozymes says Albucult confers a number of benefits to the development of R-Tech Ueno’s new therapy, including an exceptional purity profile and batch-to-batch consistency.

  • Companies:
  • Novozymes
See more

You may also like

Ingredients

Novozymes reports a good year in 2014

Read more
Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%

Trending Articles

  1. C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
  2. Quotient Sciences and Vasa Therapeutics announce dosing of first subjects in VS-041 novel heart failure trial The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of VS-041 in healthy volunteers
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. Rousselot Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global customer-base, we deliver advanced ingredient solutions that enable innovation, excite today’s consumers, and contribute to public health. Rousselot is a brand of Darling Ingredients<br><br><sup>*Global Gelatin Market Insights Forecast to 2026, Calibre Research, 2020</sup>
  5. dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient

Upcoming event

Boston Biotech Week

23-26 September, 2024 | Convention and exhibition | Boston, US See all

You may also like

Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
Ingredients

Good outlook for Novozymes after eventful 2013

Strong increase in sales of products for the manufacture of pharmaceuticals
Ingredients

Novozymes’ agreement with GSK brings payback closer

GSK is seeking approval in Europe for diabetes drug Eperzan
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Safe, consistent and sustainable hyaluronic acid

Hyaluronic acid (HA) is a naturally occurring polysaccharide ubiquitous in nature, which is distributed widely throughout connective, epithelial and neural tissues in the human body. Due to its intrinsic biocompatibility, biodegradability and diverse biological functions, HA is widely used in medical devices and pharmaceutical applications. In response to concerns surrounding the purity of many sources of HA, a <i>Bacillus subtilis</i>-based fermentation process has been developed by Novozymes Biopharma.
Ingredients

Novozymes Biopharma aligns recombinant human albumin portfolio with new brand name

Portfolio will bring together rAlbumin product line with introduction of new brand names Recombumin Alpha and Recombumin Prime
Ingredients

Enzymes cut industrial emissions and resource use

Comprehensive scientific review of existing studies shows enzyme technology is a promising means of moving towards cleaner industrial production
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Let enzymes do the work

The use of enzyme catalysts has had a real impact on the synthesis of pharmaceutical ingredients, making it possible to improve some syntheses dramatically and even make some molecules that would otherwise be either impossible or impractical to synthesise. The use of flow reactors in biocatalysis faces challenges arising from the heterogeneous slurry nature of the reaction mixture and problems with gas and liquid handling. But research is being carried out into continuous manufacturing methods for biocatalytic reactions.
Subscribe now